PSI-6130 is an experimental treatment for hepatitis C

Hepatitis C

Hepatitis C is an infectious disease primarily affecting the liver, caused by the hepatitis C virus . The infection is often asymptomatic, but chronic infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally apparent after many years...

. PSI-6130 is a member of a class of antiviral drug

Antiviral drug

Antiviral drugs are a class of medication used specifically for treating viral infections. Like antibiotics for bacteria, specific antivirals are used for specific viruses...

s known as nucleoside polymerase inhibitors

Enzyme inhibitor

An enzyme inhibitor is a molecule that binds to enzymes and decreases their activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used as herbicides and pesticides...

 that was created by chemist Jeremy L. Clark. Specifically, PSI-6130 inhibits the hepatitis C virus NS5B RNA dependant RNA polymerase.

PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128. R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.